OliX Pharmaceuticals,Inc (226950.KQ)
KRW 18430.0
(-6.07%)
KRW 18430.0
(-6.07%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 35.24 Billion KRW | 9.7% |
| 2022 | 29.72 Billion KRW | 52.07% |
| 2021 | 19.54 Billion KRW | 12.79% |
| 2020 | 17.33 Billion KRW | 14.14% |
| 2019 | 15.18 Billion KRW | 220.27% |
| 2018 | 4.74 Billion KRW | 1.49% |
| 2017 | 4.67 Billion KRW | 14.57% |
| 2016 | 4.07 Billion KRW | 34.57% |
| 2015 | 3.02 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 10.2 Billion KRW | 34.87% |
| 2024 Q2 | 7.72 Billion KRW | -17.99% |
| 2023 Q1 | 9.43 Billion KRW | 198.94% |
| 2023 FY | 32.6 Billion KRW | 9.7% |
| 2023 Q3 | 6.4 Billion KRW | -30.44% |
| 2023 Q2 | 9.2 Billion KRW | -2.45% |
| 2023 Q4 | 7.56 Billion KRW | 18.25% |
| 2022 Q3 | 8.63 Billion KRW | -4.99% |
| 2022 Q1 | 9.54 Billion KRW | 86.23% |
| 2022 FY | 29.72 Billion KRW | 52.07% |
| 2022 Q4 | 3.15 Billion KRW | -63.45% |
| 2022 Q2 | 9.08 Billion KRW | -4.78% |
| 2021 Q1 | 5.86 Billion KRW | -42.84% |
| 2021 FY | 19.54 Billion KRW | 12.79% |
| 2021 Q4 | 5.12 Billion KRW | -38.65% |
| 2021 Q2 | 5.08 Billion KRW | -13.33% |
| 2021 Q3 | 8.35 Billion KRW | 64.36% |
| 2020 Q3 | 4.71 Billion KRW | -2.25% |
| 2020 Q2 | 4.82 Billion KRW | 53.64% |
| 2020 Q1 | 3.13 Billion KRW | -42.05% |
| 2020 Q4 | 10.26 Billion KRW | 117.62% |
| 2020 FY | 17.33 Billion KRW | 14.14% |
| 2019 Q2 | 3.86 Billion KRW | 47.32% |
| 2019 Q1 | 2.62 Billion KRW | 24.74% |
| 2019 Q3 | 3.92 Billion KRW | 1.67% |
| 2019 Q4 | 5.41 Billion KRW | 37.91% |
| 2019 FY | 15.18 Billion KRW | 220.27% |
| 2018 Q4 | 2.1 Billion KRW | 0.44% |
| 2018 FY | 4.74 Billion KRW | 1.49% |
| 2018 Q3 | 2.09 Billion KRW | -5.03% |
| 2018 Q2 | 2.2 Billion KRW | 11.57% |
| 2018 Q1 | 1.97 Billion KRW | 0.0% |
| 2017 FY | 4.67 Billion KRW | 14.57% |
| 2016 FY | 4.07 Billion KRW | 34.57% |
| 2015 FY | 3.02 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Co., Ltd. | 109.98 Billion KRW | 67.951% |
| iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -349.278% |
| BINEX Co., Ltd. | 55.67 Billion KRW | 36.688% |
| Bioneer Corporation | 204.55 Billion KRW | 82.768% |
| Anterogen.Co.,Ltd. | 7.74 Billion KRW | -355.41% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | 46.031% |
| CrystalGenomics, Inc. | 32.36 Billion KRW | -8.896% |
| Helixmith Co., Ltd | 37.36 Billion KRW | 5.667% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 87.672% |
| Medy-Tox Inc. | 110.88 Billion KRW | 68.211% |
| Peptron, Inc. | 16.65 Billion KRW | -111.626% |
| Amicogen, Inc. | 52.82 Billion KRW | 33.269% |
| Genexine, Inc. | 41.62 Billion KRW | 15.323% |
| HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | -118.041% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | 64.257% |
| ALTEOGEN Inc. | 40.93 Billion KRW | 13.89% |
| PharmaResearch Co., Ltd. | 89.44 Billion KRW | 60.589% |
| SillaJen, Inc. | 5.11 Billion KRW | -589.513% |
| JETEMA, Co., Ltd. | 25.66 Billion KRW | -37.348% |
| Genomictree Inc. | 16.26 Billion KRW | -116.722% |
| MedPacto, Inc. | 26.91 Billion KRW | -30.945% |
| D&D Pharmatech | 32.16 Billion KRW | -9.596% |
| EASY BIO,Inc. | 29.67 Billion KRW | -18.798% |
| GI Innovation, Inc. | 57.59 Billion KRW | 38.795% |